{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:40:44Z","timestamp":1792370444938,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UCSF Internal Funding and see acknowledgment section--none of the funders listed came up"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Schizophrenia is a severe mental illness whose current treatments primarily target dopamine and serotonin receptors. These drugs often cause side effects and vary in effectiveness across patients. The trace amine-associated receptor 1 (TAAR1), which modulates monoamine signaling, has emerged as a promising alternative target. To discover previously unexplored TAAR1 ligands, we computationally dock 65 million molecules against the active state of TAAR1 and experimentally test 55 of those highly ranked. Fourteen TAAR1 agonists emerge with potencies ranging from mid-nanomolar to micromolar. This high functional selectivity may reflect the compact conformation adopted by the activated TAAR1 orthosteric site. While this is favorable for agonist prioritization, simulations suggest that it can be over-optimized for initial hit rates at the expense of subsequent affinity maturation. Hit optimization yields nanomolar agonists whose docking-predicted poses are confirmed by cryo-EM. Three agonists have high brain exposure and potencies, with one compound showing potency comparable to the investigational drug ulotaront and two compounds exhibiting even greater potency, at levels sufficient for behavioral studies. All three potently normalize amphetamine-induced pre-pulse inhibition in mice, a model for schizophrenia, without catalepsy, a common side effect of traditional antipsychotics.<\/jats:p>","DOI":"10.1038\/s41467-026-77484-2","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:34:47Z","timestamp":1789605287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structure based discovery of antipsychotic-like TAAR1 agonists"],"prefix":"10.1038","volume":"17","author":[{"given":"Sijie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1191","authenticated-orcid":false,"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-9262","authenticated-orcid":false,"given":"Yujin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5792-1017","authenticated-orcid":false,"given":"Joao M.","family":"Braz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Kranthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-1303","authenticated-orcid":false,"given":"Brendan W.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3893-9651","authenticated-orcid":false,"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-7754","authenticated-orcid":false,"given":"Dmytro S.","family":"Radchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6073-002X","authenticated-orcid":false,"given":"Yurii S.","family":"Moroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1195-6417","authenticated-orcid":false,"given":"John J.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-6333","authenticated-orcid":false,"given":"Allan I.","family":"Basbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-8144","authenticated-orcid":false,"given":"H. Eric","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7397","authenticated-orcid":false,"given":"William C.","family":"Wetsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-7367","authenticated-orcid":false,"given":"Brian K.","family":"Shoichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"77484_CR1","doi-asserted-by":"crossref","unstructured":"Pei, Y., Asif-Malik, A. & Canales, J. J. Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry, and clinical implications. Front. Neurosci. 10, 148 (2016).","DOI":"10.3389\/fnins.2016.00148"},{"key":"77484_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","volume":"36","author":"HH Sitte","year":"2015","unstructured":"Sitte, H. H. & Freissmuth, M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol. Sci. 36, 41\u201350 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"77484_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2007.06.007","volume":"116","author":"DK Grandy","year":"2007","unstructured":"Grandy, D. K. Trace amine-associated receptor 1\u2014Family archetype or iconoclast? Pharmacol. Ther. 116, 355\u2013390 (2007).","journal-title":"Pharmacol. Ther."},{"key":"77484_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nature05066","volume":"442","author":"SD Liberles","year":"2006","unstructured":"Liberles, S. D. & Buck, L. B. A second class of chemosensory receptors in the olfactory epithelium. Nature 442, 645\u2013650 (2006).","journal-title":"Nature"},{"key":"77484_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.107.132647","volume":"324","author":"L Lindemann","year":"2008","unstructured":"Lindemann, L. et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J. Pharmacol. Exp. Ther. 324, 948\u2013956 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"77484_CR6","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"FG Revel","year":"2011","unstructured":"Revel, F. G. et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl. Acad. Sci. USA. 108, 8485\u20138490 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77484_CR7","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1073\/pnas.0906522106","volume":"106","author":"A Bradaia","year":"2009","unstructured":"Bradaia, A. et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl. Acad. Sci. USA 106, 20081\u201320086 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77484_CR8","doi-asserted-by":"crossref","unstructured":"Yang, S. H. et al. Neural mechanism of acute stress regulation by trace aminergic signalling in the lateral habenula in male mice. Nat. Commun. 14, 2435 (2023).","DOI":"10.1038\/s41467-023-38180-7"},{"key":"77484_CR9","doi-asserted-by":"crossref","unstructured":"Liu, J. F., Wu, R. Y. & Li, J. X. TAAR1 as an emerging target for the treatment of psychiatric disorders. Pharmacol. Ther. 253, 108580 (2024).","DOI":"10.1016\/j.pharmthera.2023.108580"},{"key":"77484_CR10","doi-asserted-by":"crossref","unstructured":"Rutigliano, G., Accorroni, A. & Zucchi, R. The case for TAAR1 as a modulator of central nervous system function. Front. Pharmacol. 8, 987 (2018).","DOI":"10.3389\/fphar.2017.00987"},{"key":"77484_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1021\/acsptsci.2c00016","volume":"5","author":"PC Nair","year":"2022","unstructured":"Nair, P. C. et al. Trace amine-associated receptor 1 (TAAR1): molecular and clinical insights for the treatment of schizophrenia and related comorbidities. ACS Pharmacol. Transl. Sci. 5, 183\u2013188 (2022).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"77484_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41386-022-01504-0","volume":"48","author":"M Saarinen","year":"2023","unstructured":"Saarinen, M. et al. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1\/5-HT receptor agonist SEP-363856 (vol 47, pg 2319, 2022). Neuropsychopharmacology 48, 846\u2013846 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"77484_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","volume":"273","author":"ED Achtyes","year":"2023","unstructured":"Achtyes, E. D. et al. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 273, 1543\u20131556 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"77484_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/13543784.2023.2206559","volume":"32","author":"GH Le","year":"2023","unstructured":"Le, G. H. et al. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opin. Investig. Drugs 32, 401\u2013415 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"77484_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","volume":"566","author":"J Lyu","year":"2019","unstructured":"Lyu, J. et al. Ultra-large library docking for discovering new chemotypes. Nature 566, 224\u2013229 (2019).","journal-title":"Nature"},{"key":"77484_CR16","doi-asserted-by":"publisher","first-page":"e2000028","DOI":"10.1002\/minf.202000028","volume":"39","author":"AT Ton","year":"2020","unstructured":"Ton, A. T., Gentile, F., Hsing, M., Ban, F. & Cherkasov, A. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol. Inf. 39, e2000028 (2020).","journal-title":"Mol. Inf."},{"key":"77484_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-020-2117-z","volume":"580","author":"C Gorgulla","year":"2020","unstructured":"Gorgulla, C. et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 580, 663\u2013668 (2020).","journal-title":"Nature"},{"key":"77484_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-021-04175-x","volume":"600","author":"A Alon","year":"2021","unstructured":"Alon, A. et al. Structures of the sigma2 receptor enable docking for bioactive ligand discovery. Nature 600, 759\u2013764 (2021).","journal-title":"Nature"},{"key":"77484_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.abn7065","volume":"377","author":"EA Fink","year":"2022","unstructured":"Fink, E. A. et al. Structure-based discovery of nonopioid analgesics acting through the \u03b12A-adrenergic receptor. Science 377, 1509 (2022).","journal-title":"Science"},{"key":"77484_CR20","doi-asserted-by":"publisher","unstructured":"Gorgulla, C. et al. VirtualFlow 2.0\u2014the next generation drug discovery platform enabling adaptive screens of 69 billion molecules. Preprint at https:\/\/doi.org\/10.1101\/2023.04.25.537981 (2023).","DOI":"10.1101\/2023.04.25.537981"},{"key":"77484_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41586-021-04220-9","volume":"601","author":"AA Sadybekov","year":"2022","unstructured":"Sadybekov, A. A. et al. Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. Nature 601, 452\u2013459 (2022).","journal-title":"Nature"},{"key":"77484_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn6354","volume":"384","author":"J Lyu","year":"2024","unstructured":"Lyu, J. et al. AlphaFold2 structures guide prospective ligand discovery. Science 384, eadn6354 (2024).","journal-title":"Science"},{"key":"77484_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","volume":"6","author":"F Gentile","year":"2020","unstructured":"Gentile, F. et al. Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent. Sci. 6, 939\u2013949 (2020).","journal-title":"ACS Cent. Sci."},{"key":"77484_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"77484_CR25","doi-asserted-by":"publisher","first-page":"8800","DOI":"10.1039\/D3SC06880C","volume":"15","author":"E Gutkin","year":"2024","unstructured":"Gutkin, E. et al. In silico screening of LRRK2 WDR domain inhibitors using deep docking and free energy simulations. Chem. Sci. 15, 8800\u20138812 (2024).","journal-title":"Chem. Sci."},{"key":"77484_CR26","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1089\/ars.2024.0794","volume":"41","author":"C Hugo","year":"2024","unstructured":"Hugo, C., Asante, I., Sadybekov, A., Katritch, V. & Yassine, H. N. Development of calcium-dependent phospholipase A2 inhibitors to target cellular senescence and oxidative stress in neurodegenerative diseases. Antioxid. Redox Signal 41, 1100\u20131116 (2024).","journal-title":"Antioxid. Redox Signal"},{"key":"77484_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117753","volume":"296","author":"WHC Titulaer","year":"2025","unstructured":"Titulaer, W. H. C. et al. Docking for Smoothened antagonist chemotypes not susceptible to a vismodegib-resistance mutation. Eur. J. Med. Chem. 296, 117753 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"77484_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2421687122","volume":"122","author":"ATN Nguyen","year":"2025","unstructured":"Nguyen, A. T. N. et al. Structure-based discovery of positive allosteric modulators of the A(1) adenosine receptor. Proc. Natl. Acad. Sci. USA. 122, e2421687122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77484_CR29","doi-asserted-by":"publisher","first-page":"10255","DOI":"10.1021\/acs.jmedchem.5c00432","volume":"68","author":"ZZ Zhou","year":"2025","unstructured":"Zhou, Z. Z. et al. In silico discovery of novel potent trace amine-associated receptor TAAR1 agonists as promising drug candidates for the treatment of schizophrenia. J. Med. Chem. 68, 10255\u201310267 (2025).","journal-title":"J. Med. Chem."},{"key":"77484_CR30","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1021\/acs.jmedchem.4c00195","volume":"67","author":"ZZ Zhou","year":"2024","unstructured":"Zhou, Z. Z. et al. Structure-based design of novel G-protein-coupled receptor TAAR1 agonists as potential antipsychotic drug candidates. J. Med. Chem. 67, 4234\u20134249 (2024).","journal-title":"J. Med. Chem."},{"key":"77484_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.12688\/wellcomeopenres.21302.1","volume":"9","author":"S Siafis","year":"2024","unstructured":"Siafis, S. et al. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data. Wellcome Open Res. 9, 182 (2024).","journal-title":"Wellcome Open Res."},{"key":"77484_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/schbul\/sbad148","volume":"50","author":"T Imbriglio","year":"2024","unstructured":"Imbriglio, T. et al. Up-regulation of the trace amine receptor, TAAR-1, in the prefrontal cortex of individuals affected by schizophrenia. Schizophr. Bull. 50, 374\u2013381 (2024).","journal-title":"Schizophr. Bull."},{"key":"77484_CR33","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1016\/j.cell.2023.10.014","volume":"186","author":"P Shang","year":"2023","unstructured":"Shang, P. et al. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. Cell 186, 5347\u20135362.e24 (2023).","journal-title":"Cell"},{"key":"77484_CR34","doi-asserted-by":"crossref","unstructured":"Zilberg, G., Parpounas, A. K., Warren, A. L., Yang, S. F. & Wacker, D. Molecular basis of human trace amine-associated receptor 1 activation. Nat. Commun. 15, 108 (2024).","DOI":"10.1038\/s41467-023-44601-4"},{"key":"77484_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41586-023-06804-z","volume":"624","author":"Z Xu","year":"2023","unstructured":"Xu, Z. et al. Ligand recognition and G-protein coupling of trace amine receptor TAAR1. Nature 624, 672\u2013681 (2023).","journal-title":"Nature"},{"key":"77484_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn1524","volume":"10","author":"A Diaz-Holguin","year":"2024","unstructured":"Diaz-Holguin, A. et al. AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1. Sci. Adv. 10, eadn1524 (2024).","journal-title":"Sci. Adv."},{"key":"77484_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nlm.2013.12.015","volume":"110","author":"R Schreiber","year":"2014","unstructured":"Schreiber, R. & Newman-Tancredi, A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT receptor activation. Neurobiol. Learn. Mem. 110, 72\u201380 (2014).","journal-title":"Neurobiol. Learn. Mem."},{"key":"77484_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","volume":"49","author":"MS Kleven","year":"2005","unstructured":"Kleven, M. S., Barret-Gr\u00e9voz, C., Slot, L. B. & Newman-Tancredi, A. Novel antipsychotic agents with 5-HT agonist properties: Role of 5-HT receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49, 135\u2013143 (2005).","journal-title":"Neuropharmacology"},{"key":"77484_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-023-06775-1","volume":"624","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Recognition of methamphetamine and other amines by trace amine receptor TAAR1. Nature 624, 663\u2013671 (2023).","journal-title":"Nature"},{"key":"77484_CR40","doi-asserted-by":"crossref","unstructured":"Coleman, R. G., Carchia, M., Sterling, T., Irwin, J. J. & Shoichet, B. K. Ligand pose and orientational sampling in molecular docking. PLoS ONE 8, e75992 (2013).","DOI":"10.1371\/journal.pone.0075992"},{"key":"77484_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2174\/1568026054637683","volume":"5","author":"DM Lorber","year":"2005","unstructured":"Lorber, D. M. & Shoichet, B. K. Hierarchical docking of databases of multiple ligand conformations. Curr. Top. Med. Chem. 5, 739\u2013749 (2005).","journal-title":"Curr. Top. Med. Chem."},{"key":"77484_CR42","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0006-3495(98)77566-6","volume":"75","author":"K Gallagher","year":"1998","unstructured":"Gallagher, K. & Sharp, K. Electrostatic contributions to heat capacity changes of DNA-ligand binding. Biophys. J. 75, 769\u2013776 (1998).","journal-title":"Biophys. J."},{"key":"77484_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/prot.340170305","volume":"17","author":"EC Meng","year":"1993","unstructured":"Meng, E. C., Gschwend, D. A., Blaney, J. M. & Kuntz, I. D. Orientational sampling and rigid-body minimization in molecular docking. Proteins-Struct. Funct. Genet. 17, 266\u2013278 (1993).","journal-title":"Proteins-Struct. Funct. Genet."},{"key":"77484_CR44","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1021\/ci100214a","volume":"50","author":"MM Mysinger","year":"2010","unstructured":"Mysinger, M. M. & Shoichet, B. K. Rapid context-dependent ligand desolvation in molecular docking. J. Chem. Inf. Model. 50, 1561\u20131573 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"77484_CR45","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1038\/s41596-021-00597-z","volume":"16","author":"BJ Bender","year":"2021","unstructured":"Bender, B. J. et al. A practical guide to large-scale docking. Nat. Protoc. 16, 4799\u20134832 (2021).","journal-title":"Nat. Protoc."},{"key":"77484_CR46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1021\/acs.jcim.0c00598","volume":"61","author":"RM Stein","year":"2021","unstructured":"Stein, R. M. et al. Property-unmatched decoys in docking benchmarks. J. Chem. Inf. Model. 61, 699\u2013714 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"77484_CR47","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger, M. M., Carchia, M., Irwin, J. J. & Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55, 6582\u20136594 (2012).","journal-title":"J. Med. Chem."},{"key":"77484_CR48","doi-asserted-by":"crossref","unstructured":"Tingle, B. I. et al. ZINC-22-A free multi-billion-scale database of tangible compounds for ligand discovery. J. Chem. Inf. Model. 63, 1166 (2023).","DOI":"10.1021\/acs.jcim.2c01253"},{"key":"77484_CR49","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"77484_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1875397300802010016","volume":"2","author":"SS Wigdal","year":"2008","unstructured":"Wigdal, S. S. et al. A novel bioluminescent protease assay using engineered firefly luciferase. Curr. Chem. Genomics 2, 16\u201328 (2008).","journal-title":"Curr. Chem. Genomics"},{"key":"77484_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43506-6","volume":"14","author":"S Gahbauer","year":"2023","unstructured":"Gahbauer, S. et al. Docking for EP4R antagonists active against inflammatory pain. Nat. Commun. 14, 8067 (2023).","journal-title":"Nat. Commun."},{"key":"77484_CR52","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.1073\/pnas.0812657106","volume":"106","author":"P Kolb","year":"2009","unstructured":"Kolb, P. et al. Structure-based discovery of \u03b22-adrenergic receptor ligands. Proc. Natl. Acad. Sci. USA 106, 6843\u20136848 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77484_CR53","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1021\/cb400103f","volume":"8","author":"DR Weiss","year":"2013","unstructured":"Weiss, D. R. et al. Conformation guides molecular efficacy in docking screens of activated \u03b22-adrenergic G protein coupled receptor. ACS Chem. Biol. 8, 1018\u20131026 (2013).","journal-title":"ACS Chem. Biol."},{"key":"77484_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature19112","volume":"537","author":"A Manglik","year":"2016","unstructured":"Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185\u2013190 (2016).","journal-title":"Nature"},{"key":"77484_CR55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2027-0","volume":"579","author":"RM Stein","year":"2020","unstructured":"Stein, R. M. et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature 579, 609\u2013614 (2020).","journal-title":"Nature"},{"key":"77484_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57136-7","volume":"16","author":"TA Tummino","year":"2025","unstructured":"Tummino, T. A. et al. Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects. Nat. Commun. 16, 2237 (2025).","journal-title":"Nat. Commun."},{"key":"77484_CR57","doi-asserted-by":"publisher","unstructured":"Passaro, S. et al. Boltz-2: towards accurate and efficient binding affinity prediction. Preprint at https:\/\/doi.org\/10.1101\/2025.06.14.659707 (2025).","DOI":"10.1101\/2025.06.14.659707"},{"key":"77484_CR58","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1021\/acschemneuro.2c00086","volume":"13","author":"AM Decker","year":"2022","unstructured":"Decker, A. M. et al. Identification of a potent human trace amine-associated receptor 1 antagonist. ACS Chem. Neurosci. 13, 1082\u20131095 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"77484_CR59","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fphar.2018.00953","volume":"9","author":"VM Lam","year":"2018","unstructured":"Lam, V. M. et al. Behavioral effects of a potential novel TAAR1 antagonist. Front Pharm. 9, 953 (2018).","journal-title":"Front Pharm."},{"key":"77484_CR60","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1039\/C5MD00400D","volume":"6","author":"VM Lam","year":"2015","unstructured":"Lam, V. M. et al. Discovery of trace amine-associated receptor 1 ligands by molecular docking screening against a homology model. Medchemcomm 6, 2216\u20132223 (2015).","journal-title":"Medchemcomm"},{"key":"77484_CR61","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/cbdd.12367","volume":"84","author":"E Cichero","year":"2014","unstructured":"Cichero, E. et al. Further insights into the pharmacology of the human trace amine-associated receptors: discovery of novel ligands for TAAR1 by a virtual screening approach. Chem. Biol. Drug Des. 84, 712\u2013720 (2014).","journal-title":"Chem. Biol. Drug Des."},{"key":"77484_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nchembio.662","volume":"7","author":"J Carlsson","year":"2011","unstructured":"Carlsson, J. et al. Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 7, 769\u2013778 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"77484_CR63","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature15699","volume":"527","author":"XP Huang","year":"2015","unstructured":"Huang, X. P. et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527, 477\u2013483 (2015).","journal-title":"Nature"},{"key":"77484_CR64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nchembio.2334","volume":"13","author":"K Lansu","year":"2017","unstructured":"Lansu, K. et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat. Chem. Biol. 13, 529\u2013536 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"77484_CR65","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1021\/acs.jmedchem.1c02031","volume":"65","author":"A Levit Kaplan","year":"2022","unstructured":"Levit Kaplan, A. et al. Structure-based design of a chemical probe set for the 5-HT(5A) serotonin receptor. J. Med Chem. 65, 4201\u20134217 (2022).","journal-title":"J. Med Chem."},{"key":"77484_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic, N. et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J. Pharmacol. Exp. Ther. 371, 1\u201314 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"77484_CR67","doi-asserted-by":"crossref","unstructured":"Mantas, I. et al. Trace amine-associated receptor 1 contributes to diverse functional actions of O-phenyl-iodotyramine in mice but not to the effects of monoamine-based antidepressants. Int. J. Mol. Sci. 22, 8907 (2021).","DOI":"10.3390\/ijms22168907"},{"key":"77484_CR68","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0920-9964(00)00139-0","volume":"49","author":"DL Braff","year":"2001","unstructured":"Braff, D. L. et al. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr. Res. 49, 171\u2013178 (2001).","journal-title":"Schizophr. Res."},{"key":"77484_CR69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1021\/acsptsci.2c00202","volume":"6","author":"RB Free","year":"2023","unstructured":"Free, R. B. et al. Identification and characterization of ML321: a novel and highly selective D2 dopamine receptor antagonist with efficacy in animal models that predict atypical antipsychotic activity. ACS Pharmacol. Transl. Sci. 6, 151\u2013170 (2023).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"77484_CR70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/wcms.1121","volume":"3","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer, R., Case, D. A. & Walker, R. C. An overview of the Amber biomolecular simulation package. Wiley Interdiscip. Rev.-Comput. Mol. Sci. 3, 198\u2013210 (2013).","journal-title":"Wiley Interdiscip. Rev.-Comput. Mol. Sci."},{"key":"77484_CR71","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","volume":"60","author":"JJ Irwin","year":"2020","unstructured":"Irwin, J. J. et al. ZINC20\u2014a free ultralarge-scale chemical database for ligand discovery. J. Chem. Inf. Model. 60, 6065\u20136073 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"77484_CR72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"77484_CR73","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"77484_CR74","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D.-Struct. Biol. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. Sect. D.-Struct. Biol."},{"key":"77484_CR75","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. Sect. D.-Struct. Biol. 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. Sect. D.-Struct. Biol."},{"key":"77484_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1107\/S0909049503024130","volume":"11","author":"PD Adams","year":"2004","unstructured":"Adams, P. D. et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J. Synchrotron Radiat. 11, 53\u201355 (2004).","journal-title":"J. Synchrotron Radiat."},{"key":"77484_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"77484_CR78","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41586-022-05258-z","volume":"610","author":"AL Kaplan","year":"2022","unstructured":"Kaplan, A. L. et al. Bespoke library docking for 5-HT receptor agonists with antidepressant activity. Nature 610, 582\u2013591 (2022).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77484-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77484-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77484-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:02:30Z","timestamp":1792368150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77484-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77484"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77484-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.K.S. is a co-founder of Epiodyne, BlueDolphin, and Deep Apple Therapeutics, and serves on the science advisory boards for Schrodinger LLC, Vilya Therapeutics, Frontier Discovery Ltd, and on the SRB of Genentech. J.J.I. is a co-founder of BlueDolphin LLC and of Deep Apple Therapeutics. H.E.X. is a founder of Cascade Pharmaceutics. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10902"}}